These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 39313274)

  • 1. Effect of antiemetics on zolbetuximab-induced gastric injury and emesis in ferrets.
    Kinugasa F; Kajikawa S; Weng J; Ugawa T; Fushiki H; Yamanaka Y; Nagata M; Haggerty G; Akuzawa S; Nakazawa T; Suzuki H; Sawamoto T
    J Pharmacol Sci; 2024 Nov; 156(3):161-170. PubMed ID: 39313274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma.
    Sahin U; Türeci Ö; Manikhas G; Lordick F; Rusyn A; Vynnychenko I; Dudov A; Bazin I; Bondarenko I; Melichar B; Dhaene K; Wiechen K; Huber C; Maurus D; Arozullah A; Park JW; Schuler M; Al-Batran SE
    Ann Oncol; 2021 May; 32(5):609-619. PubMed ID: 33610734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial.
    Shitara K; Lordick F; Bang YJ; Enzinger P; Ilson D; Shah MA; Van Cutsem E; Xu RH; Aprile G; Xu J; Chao J; Pazo-Cid R; Kang YK; Yang J; Moran D; Bhattacharya P; Arozullah A; Park JW; Oh M; Ajani JA
    Lancet; 2023 May; 401(10389):1655-1668. PubMed ID: 37068504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study.
    Türeci O; Sahin U; Schulze-Bergkamen H; Zvirbule Z; Lordick F; Koeberle D; Thuss-Patience P; Ettrich T; Arnold D; Bassermann F; Al-Batran SE; Wiechen K; Dhaene K; Maurus D; Gold M; Huber C; Krivoshik A; Arozullah A; Park JW; Schuler M
    Ann Oncol; 2019 Sep; 30(9):1487-1495. PubMed ID: 31240302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of anti-claudin 18.2 monoclonal antibody zolbetuximab alone or combined with chemotherapy or programmed cell death-1 blockade in syngeneic and xenograft gastric cancer models.
    Nishibata T; Weng J; Omori K; Sato Y; Nakazawa T; Suzuki T; Yamada T; Nakajo I; Kinugasa F; Türeci Ö; Şahin U; Yoshida T
    J Pharmacol Sci; 2024 Jul; 155(3):84-93. PubMed ID: 38797537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ILUSTRO: Phase II Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma.
    Klempner SJ; Lee KW; Shitara K; Metges JP; Lonardi S; Ilson DH; Fazio N; Kim TY; Bai LY; Moran D; Yang J; Arozullah A; Park JW; Raizer JJ; Bang YJ; Shah MA
    Clin Cancer Res; 2023 Oct; 29(19):3882-3891. PubMed ID: 37490286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Highly Emetogenic Chemotherapy and Hematopoietic Cell Transplantation Regimens: The FOND-O Trial.
    Clemmons AB; Orr J; Andrick B; Gandhi A; Sportes C; DeRemer D
    Biol Blood Marrow Transplant; 2018 Oct; 24(10):2065-2071. PubMed ID: 29906570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zolbetuximab: First Approval.
    Keam SJ
    Drugs; 2024 Aug; 84(8):977-983. PubMed ID: 38967717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of three preclinical models for nausea and vomiting assessment.
    Goineau S; Castagné V
    J Pharmacol Toxicol Methods; 2016; 82():45-53. PubMed ID: 27477617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zolbetuximab for Claudin18.2-positive gastric or gastroesophageal junction cancer.
    Kubota Y; Shitara K
    Ther Adv Med Oncol; 2024; 16():17588359231217967. PubMed ID: 38188462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An interaction of ondansetron and dexamethasone antagonizing cisplatin-induced acute and delayed emesis in the ferret.
    Rudd JA; Naylor RJ
    Br J Pharmacol; 1996 May; 118(2):209-14. PubMed ID: 8735616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The novel NK1 receptor antagonist MK-0869 (L-754,030) and its water soluble phosphoryl prodrug, L-758,298, inhibit acute and delayed cisplatin-induced emesis in ferrets.
    Tattersall FD; Rycroft W; Cumberbatch M; Mason G; Tye S; Williamson DJ; Hale JJ; Mills SG; Finke PE; MacCoss M; Sadowski S; Ber E; Cascieri M; Hill RG; MacIntyre DE; Hargreaves RJ
    Neuropharmacology; 2000 Feb; 39(4):652-63. PubMed ID: 10728886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multicentre, double-blind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesis. Ondansetron Delayed Emesis Study Group.
    Olver I; Paska W; Depierre A; Seitz JF; Stewart DJ; Goedhals L; McQuade B; McRae J; Wilkinson JR
    Ann Oncol; 1996 Nov; 7(9):945-52. PubMed ID: 9006746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiemetic effect of ondansetron and dexamethasone in gynecologic malignant patients receiving chemotherapy.
    Pradermdee P; Manusirivithaya S; Tangjitgamol S; Thavaramara T; Sukwattana P
    J Med Assoc Thai; 2006 Oct; 89 Suppl 4():S29-36. PubMed ID: 17725140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of fosaprepitant for the prevention of nausea and emesis during 5 weeks of chemoradiotherapy for cervical cancer (the GAND-emesis study): a multinational, randomised, placebo-controlled, double-blind, phase 3 trial.
    Ruhlmann CH; Christensen TB; Dohn LH; Paludan M; Rønnengart E; Halekoh U; Hilpert F; Feyer P; Kristensen G; Hansen O; Keefe D; Herrstedt J
    Lancet Oncol; 2016 Apr; 17(4):509-518. PubMed ID: 26952945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 1 trial of zolbetuximab in Japanese patients with CLDN18.2+ gastric or gastroesophageal junction adenocarcinoma.
    Shitara K; Kawazoe A; Hirakawa A; Nakanishi Y; Furuki S; Fukuda M; Ueno Y; Raizer J; Arozullah A
    Cancer Sci; 2023 Apr; 114(4):1606-1615. PubMed ID: 36478334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial.
    Shah MA; Shitara K; Ajani JA; Bang YJ; Enzinger P; Ilson D; Lordick F; Van Cutsem E; Gallego Plazas J; Huang J; Shen L; Oh SC; Sunpaweravong P; Soo Hoo HF; Turk HM; Oh M; Park JW; Moran D; Bhattacharya P; Arozullah A; Xu RH
    Nat Med; 2023 Aug; 29(8):2133-2141. PubMed ID: 37524953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy, safety and feasibility of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric patients receiving moderately and highly emetogenic chemotherapy - results of a non-interventional observation study.
    Willier S; Cabanillas Stanchi KM; von Have M; Binder V; Blaeschke F; Feucht J; Feuchtinger T; Döring M
    BMC Cancer; 2019 Nov; 19(1):1118. PubMed ID: 31730451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health-related quality of life in patients with CLDN18.2-positive, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma: results from the SPOTLIGHT and GLOW clinical trials.
    Lordick F; Van Cutsem E; Shitara K; Xu RH; Ajani JA; Shah MA; Oh M; Ganguli A; Chang L; Rhoten S; Bhattacharya P; Matsangou M; Park JW; Pophale R; Ranganath R; Kang YK
    ESMO Open; 2024 Aug; 9(8):103663. PubMed ID: 39146670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of different antiemetic agents on morphine-induced emesis in ferrets.
    Wynn RL; Essien E; Thut PD
    Eur J Pharmacol; 1993 Sep; 241(1):47-54. PubMed ID: 8223924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.